Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Abstract

RIV4 provided better protection than standard-dose IIV4 against confirmed influenza-like illness among older adults. (Funded by Protein Sciences; ClinicalTrials.gov number, NCT02285998 .).